Navigation Links
Enzyme-inhibition could revolutionize molecular imaging
Date:6/9/2014

St. Louis, Mo. (June 9, 2014) The prominent role a single enzyme plays in cancer imaging has eluded researchers for years, but not anymore. This discovery could pave new avenues in nuclear medicine. The enzyme, called neutral endopeptidase (NEP), has a way of breaking down most radiopeptide imaging agents in the body. Researchers have developed an elegant new concept that improves molecular imaging, according to study results presented during the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.

The sneaky enzyme has evaded studies with peptide tracers until now because it dwells not in tested blood serum but along the walls of blood vessels and other tissues. In order to combat the degradation of circulating radiopeptides, researchers co-injected a NEP inhibitor called phosphoramidon, derived from bacteria, at the same time as an agent for imaging with single photon emission computed tomography and computed tomography (SPECT/CT). They then applied this method of enzyme inhibition in multiple imaging studies involving a range of radionuclide and peptide counterparts. The results of this research showed consistent successup to 40 times the circulating radiopeptides when protected with phosphoramidon, compared to unprotected controls. This means the simple co-injection of an enzyme inhibitor promotes dramatically improved bioavailability and metabolic stability of radiopeptide imaging agents leading to higher uptake of the agent within targeted tumors and therefore better cancer imaging.

"Oncologists have long sought a powerful 'magic bullet' that can find tumors wherever they hide in the body so that they can be imaged and then destroyed," said Marion de Jong, PhD, a principal researcher for this study conducted at Erasmus Medical Center in Rotterdam, The Netherlands in cooperation with NCSR 'Demokritos' Athens, Greece. "Following this innovative approach, we have been able to induce, for the first time, an impressive improvement in the level of circulating and viable radiopeptides, leading to a spectacular increase in tumor uptake. Enzyme-inhibition in the body could translate into higher diagnostic sensitivity and improved therapeutic efficacy of radiopeptide drugs in cancer patients."

Not only were circulating radiopeptides increased in small animal models of varying tumor types, but the accumulation of radiopeptides also peaked at 14 times that of controls, which had not been treated with enzyme-inhibiting phosphoramidon. These results were clearly visualized by SPECT/CT imaging.


'/>"/>

Contact: Kimberly Brown
kbrown@snmmi.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. A few circulating cancer cells could cue risk of metastases
2. Research could lead to new cancer assay, aid both dogs and humans
3. New definition of kidney disease for clinical trials could lead to new treatments
4. New amyloid-reducing compound could be a preventive measure against Alzheimers
5. Study explains how green tea could reduce pancreatic cancer risk
6. A cure for dry eye could be a blink away
7. Coating stents with vitamin C could reduce clotting risks
8. Could cannabis curb seizures? Experts weed through the evidence
9. Paper-based diagnostics, made with a scrapbooking tool, could curb hepatitis C pandemic
10. Pine bark substance could be potent melanoma drug
11. Biomarker test for Peripartum Cardiomyopathy could help reduce death after giving birth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... N.Y (PRWEB) , ... October 13, 2017 , ... Lori ... became a member of ElderCounsel, a national organization of elder law and special needs ... changing laws and rules. It also provides a forum to network with elder law ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network ... advocate for action towards gender equality at their inaugural Summit in New York City ... and reached a social audience of over 3 million. To watch the Mobilize Women ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ... LLC , and named its founder as Diplomat,s chief ... Tennessee , will operate under Diplomat subsidiary ... offerings for health care partners to include IT outsourcing, ... "In an interoperable world, technology delivers comprehensive insight ...
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
Breaking Medicine Technology: